Operational Costs Compared: SG&A Analysis of Zoetis Inc. and BeiGene, Ltd.

SG&A Expenses: Zoetis vs. BeiGene Over a Decade

__timestampBeiGene, Ltd.Zoetis Inc.
Wednesday, January 1, 201469300001643000000
Thursday, January 1, 201573110001532000000
Friday, January 1, 2016200970001364000000
Sunday, January 1, 2017626020001334000000
Monday, January 1, 20181953850001484000000
Tuesday, January 1, 20193882490001638000000
Wednesday, January 1, 20206001760001726000000
Friday, January 1, 20219901230002001000000
Saturday, January 1, 202212778520002009000000
Sunday, January 1, 202315045010002151000000
Monday, January 1, 20242318000000
Loading chart...

Unleashing insights

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of the pharmaceutical industry, operational efficiency is key. This analysis of Selling, General, and Administrative (SG&A) expenses from 2014 to 2023 offers a fascinating glimpse into the financial strategies of Zoetis Inc. and BeiGene, Ltd. Over this period, Zoetis Inc., a leader in animal health, maintained a steady SG&A expense, averaging around $1.7 billion annually. In contrast, BeiGene, Ltd., a rising star in biotechnology, saw its SG&A expenses skyrocket by over 21,000%, from a modest $6.93 million in 2014 to a staggering $1.5 billion in 2023. This dramatic increase reflects BeiGene's aggressive expansion and investment in research and development. As these two companies continue to navigate the competitive pharmaceutical market, their SG&A trends offer valuable insights into their strategic priorities and operational efficiencies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025